Axial Spondyloarthritis (axSpA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : May 1, 2026
- Updated On : August 27, 2026
- Pages : 154
Axial Spondyloarthritis Market Outlook and Forecast
Thelansis’s “Axial Spondyloarthritis (axSpA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Axial Spondyloarthritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Axial Spondyloarthritis (axSpA) Overview
Axial spondyloarthritis is a chronic immune-mediated inflammatory rheumatic disease affecting the sacroiliac joints and spine, causing inflammatory back pain, stiffness, impaired function, and, in some patients, progressive structural damage and spinal ankylosis. The treatment landscape has evolved from NSAIDs and other anti-inflammatory measures to targeted therapies, with TNF and IL-17 inhibitors established as major biologic options and JAK inhibitors expanding the oral treatment landscape. Despite these advances, substantial unmet needs remain, including delayed diagnosis, incomplete responses, treatment intolerance, and uncertainty over whether current therapies can reliably prevent new bone formation and long-term structural progression. This has driven development toward increasingly selective mechanisms. Bimekizumab, which simultaneously inhibits IL-17A and IL-17F, is already approved for both non-radiographic axSpA and ankylosing spondylitis, while emerging approaches such as selective ERAP1 inhibition are exploring entirely new biology. For stakeholders, axSpA represents an important therapeutic frontier where the next advance will depend not only on controlling inflammation, but on achieving durable disease control and more meaningful protection against structural progression.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Axial Spondyloarthritis Market Outlook and Forecast
Thelansis’s “Axial Spondyloarthritis (axSpA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Axial Spondyloarthritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Axial Spondyloarthritis (axSpA) Overview
Axial spondyloarthritis is a chronic immune-mediated inflammatory rheumatic disease affecting the sacroiliac joints and spine, causing inflammatory back pain, stiffness, impaired function, and, in some patients, progressive structural damage and spinal ankylosis. The treatment landscape has evolved from NSAIDs and other anti-inflammatory measures to targeted therapies, with TNF and IL-17 inhibitors established as major biologic options and JAK inhibitors expanding the oral treatment landscape. Despite these advances, substantial unmet needs remain, including delayed diagnosis, incomplete responses, treatment intolerance, and uncertainty over whether current therapies can reliably prevent new bone formation and long-term structural progression. This has driven development toward increasingly selective mechanisms. Bimekizumab, which simultaneously inhibits IL-17A and IL-17F, is already approved for both non-radiographic axSpA and ankylosing spondylitis, while emerging approaches such as selective ERAP1 inhibition are exploring entirely new biology. For stakeholders, axSpA represents an important therapeutic frontier where the next advance will depend not only on controlling inflammation, but on achieving durable disease control and more meaningful protection against structural progression.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)